HUE028605T2 - Vírusszerû részecskék tisztítása - Google Patents

Vírusszerû részecskék tisztítása Download PDF

Info

Publication number
HUE028605T2
HUE028605T2 HUE08782762A HUE08782762A HUE028605T2 HU E028605 T2 HUE028605 T2 HU E028605T2 HU E08782762 A HUE08782762 A HU E08782762A HU E08782762 A HUE08782762 A HU E08782762A HU E028605 T2 HUE028605 T2 HU E028605T2
Authority
HU
Hungary
Prior art keywords
vlps
chromatographic
vlp
chromatography
norovirus
Prior art date
Application number
HUE08782762A
Other languages
English (en)
Inventor
Thomas S Vedvick
Bryan Steadman
Charles Richardson
Thomas R Foubert
Charles R Petrie
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of HUE028605T2 publication Critical patent/HUE028605T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (6)

  1. VlRUSSZERŰ részecskék tisztítása Szabadalmi igénypontok
    1, Eprás Calidvirus ví rosszéra részecskék {Y'LP-k} tisztítására többlépéses kromatográfiás eljárás alkalmazásával, ahol a többlépéses kromatográfiás eljárás egynél több kromatográfiás anyagot alkalmaz, és ahol az eljárás egy lépése során érinikeztetönk egy ViP-tartalmö oldatot egy mefikhldrcfób kölcsön hatásos (NIC) gyantával, ahol a többlépéses kromatográfiás eljárás körülbelül ?0%-ná! nagyobb tisztaságra megtisztítja a VLF-ket
  2. 2, Az 1. igénypont szerinti eljárás, amelynél a VLP-tartálmü oldat ionerősségét úgy állítjuk be, hogy a VIP-k retencióját eredményezze és a szennyezöanyagok átfolyását a metibhidroföb kölcsönhatásös anyagon. 3, A 2, igénypont szerinti eljárás, amelynél az lonerosséget ammónlum-szulfát hozzáadásával állítjuk be.
  3. 4, Az 1, igénypont szerinti eprás, amelynél a VtP-ket körülbelül 90%~nát nagyobb tisztaságra tisztítjuk meg.
  4. 5, Az 1 igénypont szerinti eljárás, amelynél a Calidvirus VLP-k Norovirus YLP-k, $< Az 5. igénypont szerinti eljárás, amelynél a Korovirus VLP~k az I, vagy II. genoosopobba tartozó Nomvirus VLP-k,
  5. 7, Az 1, Igénypont szerinti eljárás, amelynél a többlépéses kromatográfiás eljárás tartalmaz egy kationcserés kromatográfiás lépést, amelyet követi a rneÜÍ-HIC 8. A 7, igénypont szerinti eljárás, amelynél a Vt.P~k II,. genoosoportba tartozó Norovirus VLP-k. H A 8, igénypont szerinti epirás, amelynél a íh genocsoportba tartozó Norovirus egy Houston-vlrus.
  6. 10, Az 1, igénypont szerinti eljárás, amelynél a többlépéses eljárást rekombináns módszerek alkalmazásával előállított sejtlizátymon vagy tenyészeí-fetylészón 11, A 10. igénypont szerinti eljárás, amelynél a VtP-kei bakteriális sejtekben, rovarsejtekben, élesztősejtekben vagy emíöseredető sejtekben termeltetjük. 12, A 11, igénypont szerinti eljárás, amelynél a gazdasejt DNSéarfalmában 1 linói kisebb a szennyezők szintje, 13, A 11 igénypont szerinti eljárás, amelynél a gazdasejt fehérjetartalmában Síinél kisebb a szennyezők szintje.
HUE08782762A 2007-03-14 2008-03-14 Vírusszerû részecskék tisztítása HUE028605T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90682107P 2007-03-14 2007-03-14

Publications (1)

Publication Number Publication Date
HUE028605T2 true HUE028605T2 (hu) 2016-12-28

Family

ID=39760420

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08782762A HUE028605T2 (hu) 2007-03-14 2008-03-14 Vírusszerû részecskék tisztítása

Country Status (13)

Country Link
US (4) US8481693B2 (hu)
EP (1) EP2134360B1 (hu)
JP (4) JP5284290B2 (hu)
KR (3) KR20150098681A (hu)
AU (1) AU2008224877B2 (hu)
CA (1) CA2683977C (hu)
DK (1) DK2134360T3 (hu)
ES (1) ES2559421T3 (hu)
HK (1) HK1138795A1 (hu)
HU (1) HUE028605T2 (hu)
PL (1) PL2134360T3 (hu)
SG (2) SG10201701988TA (hu)
WO (1) WO2008113011A2 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2618885T3 (es) 2006-09-29 2017-06-22 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
AU2008224877B2 (en) 2007-03-14 2013-07-11 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR20100083150A (ko) 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
SG10201403290SA (en) 2009-06-16 2014-10-30 Genzyme Corp Improved methods for purification of recombinant aav vectors
EP2449096A4 (en) * 2009-07-03 2014-01-08 Univ Queensland PROCESS FOR PREPARING A PARTICULATE BIOLOGICAL STRUCTURE
US20110142863A1 (en) 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules
EP2524215B1 (en) 2010-01-15 2018-12-26 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
SG184833A1 (en) * 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
FI122520B (fi) * 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
JP5881744B2 (ja) 2011-02-02 2016-03-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド アルカリ溶液でのアパタイトの表面中和方法
BR112014000656A2 (pt) * 2011-07-11 2017-02-14 Takeda Vaccines Inc formulações de vacina parenteral contra norovírus
EP2554664A1 (de) * 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
CN104023745B (zh) * 2011-12-30 2016-12-07 德国癌症研究中心 用于接种目的的来自eb病毒的第二代病毒样颗粒(vlp)
CN104507952B (zh) 2012-05-30 2018-08-10 生物辐射实验室股份有限公司 基于磷灰石的色谱树脂的原位恢复
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR20150118155A (ko) * 2013-02-22 2015-10-21 에이전시 포 사이언스, 테크놀로지 앤드 리서치 음성 하전된 입자들을 갖는 바이러스 제제들의 크로마토그래피 정제
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JP2015017065A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ノロウイルスのウイルス様粒子を含む医薬組成物
AU2014329403B2 (en) 2013-10-03 2020-10-08 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
US9802822B2 (en) 2014-06-23 2017-10-31 Bio-Rad Laboratories, Inc. Apatite pretreatment
EP3157551B1 (en) 2014-06-23 2023-02-15 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
CN114008067A (zh) * 2019-07-04 2022-02-01 株式会社钟化 病毒或病毒样颗粒的纯化方法
EP4206329A1 (en) * 2020-08-28 2023-07-05 Kaneka Corporation Method for purifying useful substance
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
DE69535018T2 (de) * 1994-05-16 2007-02-15 Merck & Co., Inc. Papillomavirus vakzine
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3316325B2 (ja) 1994-12-20 2002-08-19 富士シリシア化学株式会社 ビール安定化処理用シリカゲル及びその製造方法並びにビールの安定化処理方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
ES2268787T3 (es) 1997-09-05 2007-03-16 Medimmune, Inc. Metodo in vitro de desmontaje/embalaje de particulas similares a virus (vlp) de papilomavirus.
DE19823814A1 (de) 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
SI1105466T1 (sl) * 1998-08-14 2006-08-31 Merck & Co Inc Postopek za ciscenje virusu podobnih delcev humanega papilomskega virusa
US6349843B1 (en) 1999-04-01 2002-02-26 The Vollrath Company Llc Pan removal ramp
AU768992B2 (en) * 1999-06-22 2004-01-15 Denka Seiken Co., Ltd. SRSV detection kit
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
JP2003066021A (ja) 2001-08-28 2003-03-05 Hiroshi Shionoya 連続分取液体クロマトグラフィー装置とそれを用いる方法
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
US20060234226A1 (en) * 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
WO2005032457A2 (en) * 2003-07-21 2005-04-14 Boyce Thompson Institute For Plant Research, Inc. Vectors and methods for immunization against norwalk virus using transgenic plants
US7481997B1 (en) * 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
WO2006138514A2 (en) * 2005-06-16 2006-12-28 Children's Hospital Medical Center Novel norovirus particle for use as an antiviral or vaccine
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
CA2659275C (en) 2006-07-27 2017-01-10 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
ES2618885T3 (es) * 2006-09-29 2017-06-22 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
AU2008224877B2 (en) 2007-03-14 2013-07-11 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
EP2027875A1 (en) 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
KR20100083150A (ko) 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
EP2235165A1 (en) 2007-12-21 2010-10-06 Cytos Biotechnology AG Process for clarifying cell homogenates
JP5852883B2 (ja) * 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
AU2009319979B2 (en) 2008-11-03 2016-10-20 Takeda Vaccines, Inc. Improved methods for isolating enveloped virus-based VLPs free of infectious agents
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
KR20120125627A (ko) * 2010-01-21 2012-11-16 리고사이트 파머슈티컬즈 인코퍼레이티드 칼리시바이러스 바이러스 유사 입자들 상에 표적화된 이종 항원 제공
US9193760B2 (en) 2010-09-20 2015-11-24 Bio-Rad Laboratories, Inc. Dissociation of product-complexed contaminants in chromatography
FI122520B (fi) 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CN102260651A (zh) 2011-06-24 2011-11-30 华中科技大学同济医学院附属协和医院 一种纯化病毒样颗粒蛋白的方法及其应用
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法

Also Published As

Publication number Publication date
US20160317645A1 (en) 2016-11-03
JP2013176392A (ja) 2013-09-09
US20190282686A1 (en) 2019-09-19
AU2008224877B2 (en) 2013-07-11
ES2559421T3 (es) 2016-02-12
CA2683977A1 (en) 2008-09-18
JP2017086090A (ja) 2017-05-25
KR20100015562A (ko) 2010-02-12
US10172930B2 (en) 2019-01-08
WO2008113011A3 (en) 2008-12-24
SG10201701988TA (en) 2017-04-27
JP5284290B2 (ja) 2013-09-11
SG179488A1 (en) 2012-04-27
EP2134360B1 (en) 2015-11-18
DK2134360T3 (en) 2016-02-22
EP2134360A2 (en) 2009-12-23
US20100150961A1 (en) 2010-06-17
WO2008113011A2 (en) 2008-09-18
US20130344107A1 (en) 2013-12-26
HK1138795A1 (zh) 2010-09-03
US8481693B2 (en) 2013-07-09
US10792353B2 (en) 2020-10-06
KR20150098681A (ko) 2015-08-28
US9359410B2 (en) 2016-06-07
JP2010530734A (ja) 2010-09-16
EP2134360A4 (en) 2011-08-24
AU2008224877A1 (en) 2008-09-18
PL2134360T3 (pl) 2016-05-31
KR101576219B1 (ko) 2015-12-10
CA2683977C (en) 2017-04-25
KR20170001720A (ko) 2017-01-04
JP2019068846A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US10792353B2 (en) Virus like particle purification
CN101490248B (zh) 纯化流感病毒的方法
Li et al. A hydrophobic interaction chromatography strategy for purification of inactivated foot-and-mouth disease virus
Tseng et al. A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography
Sviben et al. Recovery of infective virus particles in ion-exchange and hydrophobic interaction monolith chromatography is influenced by particle charge and total-to-infective particle ratio
Kalbfuss-Zimmermann et al. Viral vaccines purification
US20210292788A1 (en) Method for Adenovirus Purification
AU2013242822B2 (en) Virus like particle purification
AU2016269506A1 (en) Virus like particle purification
JP2023529187A (ja) 混入ｄｎａをより効果的に除去するための、アデノ随伴ウイルスの精製の強化
JP2024074802A (ja) アデノウイルス精製の方法
Alves Production, concentration and purification strategies for Bluetongue virus
Burden Monolith absorbants as a capture step for virus-like particles